Description
| Description | meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia. |
| In vivo | Compared to control group, meplazumab treatment significantly improved the discharged (p=0.006) and case severity (p=0.021) in critical and severe patients.?The time to virus negative in meplazumab group was reduced than that in control group (median 3, 95%CI[1.5-4.5] vs. 13, [6.5-19.5];?p=0.014, HR=0.37, 95%CI[0.155-0.833]).?The percentages of patients recovered to the normal lymphocyte count and CRP concentration were also increased remarkably and rapidly in meplazumab group.?No adverse effect was found in meplazumab-treated patients.?Interpretation:Meplazumab efficiently improved the recovery of patients with SARS-CoV-2 pneumonia with a favorable safety profile. |
| Molecular Weight |
N/A |
| CAS No. | T9931 |
Storage
store at -20 ℃
Solubility Information
( < 1 mg/ml refers to the product slightly soluble or insoluble )
